Targeting PD-1/PD-L1 interactions for cancer immunotherapy

被引：306

作者：

Zitvogel, Laurence ^{[1
,2
,3
,4
]}

Kroemer, Guido ^{[3
,5
,6
,7
,8
]}

机构：

[1] Inst Gustave Roussy, INSERM, U1015, F-94805 Villejuif, France

[2] Inst Gustave Roussy, Ctr Clin Invest CBT507, Villejuif, France

[3] Inst Gustave Roussy, Villejuif, France

[4] Univ Paris 11, Villejuif, France

[5] INSERM, U848, Villejuif, France

[6] Ctr Rech Cordeliers, Paris, France

[7] Hop Europeen Georges Pompidou, Paris, France

[8] Univ Paris 05, Fac Med, Paris, France

来源：

ONCOIMMUNOLOGY | 2012年 / 1卷 / 08期

关键词：

CELL CARCINOMA PATIENTS; CLINICAL-SIGNIFICANCE; PD-1; PATHWAY; B7-H1; EXPRESSION; MOLECULE; IMMUNOSUPPRESSION; RECEPTORS; LIGAND-1; ANTIBODY;

D O I：

10.4161/onci.21335

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1223 / 1225

页数：3

共 33 条

[11] Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade [J].

Iwai, Y ;

Ishida, M ;

Tanaka, Y ;

Okazaki, T ;

Honjo, T ;

Minato, N .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (19) :12293-12297

[12] Tissue expression of PD-L1 mediates peripheral T cell tolerance [J].

Keir, ME ;

Liang, SC ;

Guleria, I ;

Latchman, YE ;

Qipo, A ;

Albacker, LA ;

Koulmanda, M ;

Freeman, GJ ;

Sayegh, MH ;

Sharpe, AH .

JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 203 (04) :883-895

[13] Facilitation of β selection and modification of positive selection in the thymus of PD-1-deficient mice [J].

Nishimura, H ;

Honjo, T ;

Minato, N .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (05) :891-897

[14] Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer [J].

Nomi, Takeo ;

Sho, Masayuki ;

Akahori, Takahiro ;

Hamada, Kaoru ;

Kubo, Atsushi ;

Kanehiro, Hiromichi ;

Nakamura, Shinji ;

Enomoto, Koji ;

Yagita, Hideo ;

Azuma, Miyuki ;

Nakajima, Yoshiyuki .

CLINICAL CANCER RESEARCH, 2007, 13 (07) :2151-2157

[15] Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer [J].

Ohigashi, Y ;

Sho, M ;

Yamada, Y ;

Tsurui, Y ;

Hamada, K ;

Ikeda, N ;

Mizuno, T ;

Yoriki, R ;

Kashizuka, H ;

Yane, K ;

Tsushima, F ;

Otsuki, N ;

Yagita, H ;

Azuma, M ;

Nakajima, Y .

CLINICAL CANCER RESEARCH, 2005, 11 (08) :2947-2953

[16] The PD-1-PD-L pathway in immunological tolerance [J].

Okazaki, T ;

Honjo, T .

TRENDS IN IMMUNOLOGY, 2006, 27 (04) :195-201

[17] PD-1 and PD-1 ligands: from discovery to clinical application [J].

Okazaki, Taku ;

Honjo, Tasuku .

INTERNATIONAL IMMUNOLOGY, 2007, 19 (07) :813-824

[18] CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms [J].

Parry, RV ;

Chemnitz, JM ;

Frauwirth, KA ;

Lanfranco, AR ;

Braunstein, I ;

Kobayashi, SV ;

Linsley, PS ;

Thompson, CB ;

Riley, JL .

MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (21) :9543-9553

[19] Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma [J].

Parsa, Andrew T. ;

Waldron, James S. ;

Panner, Amith ;

Crane, Courtney A. ;

Parney, Ian F. ;

Barry, Jeffrey J. ;

Cachola, Kristine E. ;

Murray, Joseph C. ;

Tihan, Tarik ;

Jensen, Michael C. ;

Mischel, Paul S. ;

Stokoe, David ;

Pieper, Russell O. .

NATURE MEDICINE, 2007, 13 (01) :84-88

[20] Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4 [J].

Probst, HC ;

McCoy, K ;

Okazaki, T ;

Honjo, T ;

van den Broek, M .

NATURE IMMUNOLOGY, 2005, 6 (03) :280-286

← 1 2 3 4 →